AU2013289854B2 - Risk stratification in influenza - Google Patents

Risk stratification in influenza Download PDF

Info

Publication number
AU2013289854B2
AU2013289854B2 AU2013289854A AU2013289854A AU2013289854B2 AU 2013289854 B2 AU2013289854 B2 AU 2013289854B2 AU 2013289854 A AU2013289854 A AU 2013289854A AU 2013289854 A AU2013289854 A AU 2013289854A AU 2013289854 B2 AU2013289854 B2 AU 2013289854B2
Authority
AU
Australia
Prior art keywords
level
patient
gene product
seq
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013289854A
Other languages
English (en)
Other versions
AU2013289854A2 (en
AU2013289854A1 (en
Inventor
Anthony MCLEAN
Grant Peter Parnell
Maryam SHOJAEI
Benjamin Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTRICT
Original Assignee
NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR filed Critical NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR
Priority to AU2013289854A priority Critical patent/AU2013289854B2/en
Publication of AU2013289854A1 publication Critical patent/AU2013289854A1/en
Publication of AU2013289854A2 publication Critical patent/AU2013289854A2/en
Application granted granted Critical
Publication of AU2013289854B2 publication Critical patent/AU2013289854B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013289854A 2012-07-10 2013-07-10 Risk stratification in influenza Ceased AU2013289854B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013289854A AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
AU2012902954 2012-07-10
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza
AU2013289854A AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (3)

Publication Number Publication Date
AU2013289854A1 AU2013289854A1 (en) 2015-01-22
AU2013289854A2 AU2013289854A2 (en) 2015-02-26
AU2013289854B2 true AU2013289854B2 (en) 2016-03-24

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013289854A Ceased AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Country Status (10)

Country Link
US (2) US10036075B2 (enExample)
EP (1) EP2872891B1 (enExample)
JP (1) JP6097388B2 (enExample)
KR (1) KR20150040289A (enExample)
CN (1) CN104769430B (enExample)
AU (1) AU2013289854B2 (enExample)
BR (1) BR112015000685A2 (enExample)
CA (1) CA2877400A1 (enExample)
DK (1) DK2872891T3 (enExample)
WO (1) WO2014008545A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
WO2017149547A1 (en) * 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2019236768A1 (en) * 2018-06-05 2019-12-12 Washington University Nasal genes used to identify, characterize, and diagnose viral respiratory infections
US20230176074A1 (en) * 2020-04-09 2023-06-08 B.R.A.H.M.S Gmbh Biomarkers for the diagnosis of respiratory tract infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208496A1 (en) * 2002-08-06 2005-09-22 Genox Research, Inc. Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20120114661A1 (en) * 2009-05-26 2012-05-10 Ginsburg Geoffrey S Methods of identifying infectious disease and assays for identifying infectious disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
JP2008504803A (ja) * 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
SG177956A1 (en) * 2006-08-11 2012-02-28 Baylor Res Inst Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
CN102112878A (zh) * 2008-06-06 2011-06-29 国立大学法人富山大学 用于检测流感病毒的装置
US20120009148A1 (en) * 2008-12-29 2012-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
JP2014501489A (ja) * 2009-07-06 2014-01-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド 細胞ベースのバイオプロセシング
WO2011038363A2 (en) * 2009-09-28 2011-03-31 The Regents Of The University Of California Beta-defensin 2 genetic variation predicts h. pylori susceptibility
US20140228243A1 (en) 2011-09-04 2014-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208496A1 (en) * 2002-08-06 2005-09-22 Genox Research, Inc. Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20120114661A1 (en) * 2009-05-26 2012-05-10 Ginsburg Geoffrey S Methods of identifying infectious disease and assays for identifying infectious disease

Also Published As

Publication number Publication date
EP2872891B1 (en) 2019-03-13
CN104769430A (zh) 2015-07-08
EP2872891A4 (en) 2016-01-20
CN104769430B (zh) 2018-12-14
US10036075B2 (en) 2018-07-31
KR20150040289A (ko) 2015-04-14
JP6097388B2 (ja) 2017-03-15
AU2013289854A2 (en) 2015-02-26
JP2015530868A (ja) 2015-10-29
DK2872891T3 (da) 2019-05-13
BR112015000685A2 (pt) 2017-11-28
CA2877400A1 (en) 2014-01-16
US20180298455A1 (en) 2018-10-18
AU2013289854A1 (en) 2015-01-22
EP2872891A1 (en) 2015-05-20
WO2014008545A1 (en) 2014-01-16
US20150322538A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
US10036075B2 (en) Risk stratification in influenza
JP5555626B2 (ja) 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US20190367984A1 (en) Methods for predicting response to anti-tnf therapy
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
EP4163393B1 (en) Prediction of therapeutic response in inflammatory conditions
JP2010535825A5 (enExample)
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
WO2008043566A2 (en) Compositions and methods for treating and diagnosing irritable bowel syndrome
US20230003719A1 (en) Materials and methods for inflammatory molecular markers
US20230014092A1 (en) Materials and methods for monitoring inflammation
KR101620274B1 (ko) 비만의 진단용 조성물 및 이의 용도
WO2011065168A1 (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
US20140221235A1 (en) Biomarker algorithm for determining the time of stroke symptom onset and method
WO2015103664A1 (en) Risk stratification in influenza
CN118159668A (zh) 用于确定呼吸道感染风险的方法
WO2011041725A2 (en) Schizophrenia treatment response biomarkers
Sayed Mahmoud Marie et al. Gene expression of CD70 and CD27 is increased in alopecia areata lesions and associated with disease severity and activity
Zhao et al. Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis
Fadhil et al. Nuclear factor-kappa B gene polymorphism and interleukin-8 in Iraqi population with severe chronic periodontitis
EP4230749A1 (en) In vitro method for predicting a risk of post-chikungunya chronic inflammatory joint disease
US20250297314A1 (en) Determining the risk of death of a subject infected with a respiratory virus by measuring the expression level of the cd74 gene
RU2749248C1 (ru) Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб с использованием эпигенетических маркеров
WO2025041146A1 (en) Markers of resistance and systemic inflammation and uses thereof
US20250298015A1 (en) Diagnostic method of detecting inflammation biomarker(s)

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired